Axcentua Pharmaceuticals AB

Axcentua Pharmaceutical receives approval from the Swedish Medical Product Agency for starting clinical trials with AXP107-11

Pressmeddelande   •   Sep 14, 2010 14:08 CEST

On August 26th, 2010 Axcentua Pharmaceuticals received approval from the Swedish Medical Product Agency to initiate phase Ib/IIa clinical trials with its lead compound AXP107-11 for the treatment of patients with pancreatic cancer.

The studies will be conducted at the Karolinska University Hospital, Huddinge and at the Sahlgrenska University Hospital in Gothenburg and are designed as an open-label trial, starting with a dose-finding study (Ib) which continues over to an efficacy study (IIa). AXP107-11 is a crystal re-engineered natural compound which has been developed from bench to clinic within 2 years.

“This is a major milestone for Axcentua Pharmaceuticals and we are excited to take AXP107-11 into man and to provide a novel therapeutic approach to a disease with such a large medical need. It also validates Axcentua’s business idea of accelerated drug development, enhancing the flow of novel investigational new drugs to the clinic by using crystal re-engineering of natural compounds.” says Dr. Stefan Rehnmark, CEO of Axcentua Pharmaceuticals.

About Axcentua Pharmaceuticals:

Axcentua Pharmaceuticals is a privately held early clinical development stage pharmaceutical company committed to the generation of investigational new drugs for diseases with high unmet medical need. The company was founded in 2007 by Dr. Anders Berkenstam, Dr. Stefan Rehnmark and Dr. Michael Robin Witt. Axcentua is pioneering a crystal re-engineering strategy of natural compounds as a novel approach in drug development. Candidate drugs can be developed faster, with less risk and at a fraction of the cost as compared to traditional drug development.

Natural compounds have a proven track record as drugs and represent a largely untapped resource of new drug development candidates. However, natural compounds may have unfavorable drug-like properties and intellectual property issues have hindered development of these compounds into successful drugs. By improving the drug-like qualities and obtaining IP on novel forms, Axcentua’s crystal re-engineering strategy opens up new opportunities to explore and develop this rich source of small molecule compounds into drugs with clear pharmaceutical benefits.


For further information please contact:
Dr. Stefan Rehnmark, CEO
+46 8 524 88 620
+46 73 6478842
www.axcentua.com

Axcentua is a privately held early clinical development stage pharmaceutical company committed to the rapid generation of investigational new drugs for diseases with high unmet medical need, with an initial focus on cancer. The Company is pioneering the field of "crystal re-engineering" of natural compounds as an alternative drug development strategy to arrive at novel drugs with clear clinical benefits more rapidly, with less risk and at a fraction of the cost compared to traditional drug development strategies.